Choroidal folds and retinal pigment epithelium tear following intravitreal bevacizumab injection for exudative age-related macular degeneration.
Kawashima
Miwako
M
Division of Ophthalmology, Department of Visual Science, Nihon University School of Medicine, Tokyo, Japan.
Mori
Ryusaburo
R
Division of Ophthalmology, Department of Visual Science, Nihon University School of Medicine, Tokyo, Japan. ryu-m@sa2.so-net.ne.jp.|Department of Ophthalmology, Surugadai Hospital of Nihon University, 1-8-13, Kanda Surugadai, Chiyoda-ku, Tokyo, 101-8309, Japan. ryu-m@sa2.so-net.ne.jp.
Mizutani
Yoshihiro
Y
Division of Ophthalmology, Department of Visual Science, Nihon University School of Medicine, Tokyo, Japan.
Yuzawa
Mitsuko
M
Division of Ophthalmology, Department of Visual Science, Nihon University School of Medicine, Tokyo, Japan.
D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015862:Choroid Diseases / Q000209:etiology*; D004396:Coloring Agents; D005122:Exudates and Transudates; D005451:Fluorescein Angiography; D006801:Humans; D007208:Indocyanine Green; D007267:Injections / Q000009:adverse effects*; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D010857:Pigment Epithelium of Eye / Q000473:pathology*; D012422:Rupture, Spontaneous; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004396:Coloring Agents; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D007208:Indocyanine Green